Evidence map›Paper›PMID 26407069›Full record

ArticlePloS one2015

Expression of the Receptor Tyrosine Kinase EphB2 on Dendritic Cells Is Modulated by Toll-Like Receptor Ligation but Is Not Required for T Cell Activation.

Patrice N Mimche, Lauren M Brady, Shirley Keeton, David S J Fenne, Thayer P King, Kendra M Quicke, Lauren E Hudson, Tracey J Lamb

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. The Roles of EphB2 in Cancer.Frontiers in cell and developmental biology · 2022
    Review
  3. Immunobiology of Atherosclerosis: A Complex Net of Interactions.International journal of molecular sciences · 2019
    Review
  4. Review
  5. Mechanisms of foam cell formation in atherosclerosis.Journal of molecular medicine (Berlin, Germany) · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Patrice N MimcheDivision of Infectious Diseases, Department of Pediatric, Emory University School of Medicine, Emory University, Atlanta, Georgia, United States of America.
Lauren M BradyDivision of Infectious Diseases, Department of Pediatric, Emory University School of Medicine, Emory University, Atlanta, Georgia, United States of America.
Shirley KeetonInstitute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, Berkshire, United Kingdom.
David S J FenneInstitute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, Berkshire, United Kingdom.
Thayer P KingDivision of Infectious Diseases, Department of Pediatric, Emory University School of Medicine, Emory University, Atlanta, Georgia, United States of America.
Kendra M QuickeDivision of Infectious Diseases, Department of Pediatric, Emory University School of Medicine, Emory University, Atlanta, Georgia, United States of America.
Lauren E HudsonDivision of Infectious Diseases, Department of Pediatric, Emory University School of Medicine, Emory University, Atlanta, Georgia, United States of America.
Tracey J LambDivision of Infectious Diseases, Department of Pediatric, Emory University School of Medicine, Emory University, Atlanta, Georgia, United States of America.
Emory University · USUniversity of Reading · GB

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
Ephrin ligands as novel targets for an adjunct therapy in cerebral malariaR21NS085382 · NINDS · EMORY UNIVERSITY · PI LAMB, TRACEY JANE · 2014 to 2015
$437k
NIGMS NIH HHS T32 GM008169NINDS NIH HHS 1R21NS085382-01A1NINDS NIH HHS R21 NS085382
6 · The paper itself

Abstract

The Eph receptor tyrosine kinases interact with their ephrin ligands on adjacent cells to facilitate contact-dependent cell communication. Ephrin B ligands are expressed on T cells and have been suggested to act as co-stimulatory molecules during T cell activation. There are no detailed reports of the expression and modulation of EphB receptors on dendritic cells, the main antigen presenting cells that interact with T cells. Here we show that mouse splenic dendritic cells (DC) and bone-marrow derived DCs (BMDC) express EphB2, a member of the EphB family. EphB2 expression is modulated by ligation of TLR4 and TLR9 and also by interaction with ephrin B ligands. Co-localization of EphB2 with MHC-II is also consistent with a potential role in T cell activation. However, BMDCs derived from EphB2 deficient mice were able to present antigen in the context of MHC-II and produce T cell activating cytokines to the same extent as intact DCs. Collectively our data suggest that EphB2 may contribute to DC responses, but that EphB2 is not required for T cell activation. This result may have arisen because DCs express other members of the EphB receptor family, EphB3, EphB4 and EphB6, all of which can interact with ephrin B ligands, or because EphB2 may be playing a role in another aspect of DC biology such as migration.

Indexed as

Gene Expression RegulationAnimalsCD4-Positive T-LymphocytesCell LineCytokinesDendritic CellsFemaleHistocompatibility Antigens Class IIHumansInflammation MediatorsLigandsLymphocyte ActivationMiceMice, KnockoutProtein BindingReceptor, EphB2CytokinesHistocompatibility Antigens Class IIInflammation MediatorsLigandsReceptor, EphB2Toll-Like Receptors

Identifiers

PMID26407069
PMCPMC4583388
OpenAlexW2230745727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.